Targets › NECTIN4
17 programs from 15 companies in 76 trials: 41 Phase 2, 26 Phase 1, 7 Phase 3, 2 Phase 4; Oncology, Genitourinary; next expected readout Dec 2026.
Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells.; FUNCTION: (Microbial infection) Acts as a receptor for measles virus. (UniProt, Q96NY8)
Open in Phaseline: the race on NECTIN4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Astellas | Enfortumab Vedotin Nectin-4 binding agent; Tubulin inhibitor | NECTIN4, Tubulin | Phase 4 | Metastatic Urothelial Carcinoma; Urothelial Cancer; Locally Advanced or Metastatic Malignant Solid Tumors; Muscle-invasive Bladder Cancer … | Dec 2026 |
| Mabwell (Shanghai) Bioscience | 9MW2821 nectin-4 antibody-drug conjugate with MMAE payload | NECTIN4 | Phase 3 | Advanced Urothelial Carcinoma; Urothelial Carcinoma; Cervical Cancer; Triple-Negative Breast Cancer | Dec 2026 |
| Merck & Co. (MSD) | EV (Enfortumab Vedotin) Nectin-4 binding agent; Tubulin inhibitor | NECTIN4, Tubulin | Phase 3 | Urinary Bladder Cancer, Muscle-invasive; Bladder Cancer; Metastatic Urothelial Carcinoma | May 2027 |
| Tianjin ConjuStar Biologics | SC-101 anti-NECTIN4 antibody-drug conjugate | NECTIN4 | Phase 2 | TNBC - Triple-Negative Breast Cancer; Advanced Solid Tumor | Mar 2027 |
| Akeso | AK146D1 Anti-Trop2/Nectin4 bispecific antibody-drug conjugate | TROP2, NECTIN4 | Phase 2 | Advanced Non Small Cell Lung Cancer (NSCLC); Advanced Breast Cancer; Advanced Solid Tumors | May 2027 |
| BicycleTx | Zelenectide pevedotin anti-NECTIN4 antibody-drug conjugate | NECTIN4 | Phase 2 | Metastatic Urothelial Cancer; Breast Cancer; Non-Small Cell Lung Cancer | Mar 2028 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Becotatug Vedotin Anti-NECTIN4 antibody-drug conjugate | NECTIN4 | Phase 2 | Head and Neck Cancer | Jun 2028 |
| BeiGene | BGB-A445 anti-NECTIN4 antibody-drug conjugate | NECTIN4 | Phase 2 | Non-small Cell Lung Cancer; Urothelial Carcinoma | – |
| Adcentrx Therapeutics | ADRX-0706 anti-Nectin-4 antibody-drug conjugate | NECTIN4 | Phase 1 | Solid Tumors | Dec 2026 |
| BicycleTx | BT7480 Bicyclic peptide targeting Nectin-4 | NECTIN4 | Phase 1 | Advanced Solid Tumor | Dec 2026 |
| BicycleTx | BT8009 Bicyclic Toxin Conjugate (BTC) targeting Nectin-4-expressing malignancies | NECTIN4 | Phase 1 | Urinary Bladder Neoplasm | Jan 2027 |
| Beijing Biotech | EB-DT-NK-UC101 Allogeneic dual-target Nectin-4/HER2 CAR-NK cells with inducible caspase-9 safety switch | NECTIN4, ERBB2 | Phase 1 | Bladder Cancer | Jun 2027 |
| Regeneron Pharmaceuticals | REGN5678 Anti-NECTIN4 antibody | NECTIN4 | Phase 1 | Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Castration-resistant Prostate Cancer | Nov 2027 |
| Aktis Oncology | [225Ac]Ac-AKY-1189 Nectin-4 targeted alpha-emitting radiopharmaceutical | NECTIN4 | Phase 1 | Urothelial Carcinoma Bladder | Dec 2027 |
| Innate Pharma | IPH4502 Nectin-4-directed antibody-drug conjugate (ADC) | NECTIN4 | Phase 1 | Advanced or Metastatic Solid Tumors | Apr 2028 |
| Context Therapeutics | CT-202 Nectin-4 directed bispecific antibody engaging T cells | NECTIN4 | Phase 1 | Triple Negative Breast Cancer (TNBC) | Jan 2030 |
| Samsung Bioepis | E303 nectin-4 targeting antibody-drug conjugate | NECTIN4 | Phase 1 | Advanced Solid Tumors | Jul 2030 |
Urothelial Carcinoma (9) Bladder Cancer (7) Metastatic Urothelial Carcinoma (4) Advanced Urothelial Carcinoma (3) Urothelial Cancer (3) Locally Advanced Bladder Urothelial Carcinoma (3) Advanced Solid Tumors (3) Advanced Solid Tumor (2) Metastatic Castration-resistant Prostate Cancer (2) Cervical Cancer (1) Triple-Negative Breast Cancer (1) Urothelial Carcinoma Bladder (1)
small molecule (9), mixed (5), antibody (3)
BicycleTx (3) Mabwell (Shanghai) Bioscience (1) Aktis Oncology (1) Tianjin ConjuStar Biologics (1) Regeneron Pharmaceuticals (1) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) Innate Pharma (1) Astellas (1) Samsung Bioepis (1) Beijing Biotech (1) Akeso (1) Context Therapeutics (1) Adcentrx Therapeutics (1) BeiGene (1) Merck & Co. (MSD) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.